Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995;252(3):159-62.
doi: 10.1007/BF00178104.

Interleukin-6 and acute-phase proteins in head and neck cancer

Affiliations

Interleukin-6 and acute-phase proteins in head and neck cancer

O Gallo et al. Eur Arch Otorhinolaryngol. 1995.

Abstract

The acute-phase response is the answer of the organism to a disturbance of its homeostasis and is characterized by dramatic changes in the concentration of some plasma proteins defined as acute-phase proteins. In recent years several data have shown that interleukin-6 (IL-6) is the major inducer of acute-phase protein synthesis in human hepatocytes. Recently, we demonstrated higher IL-6 serum levels in head and neck cancer (HNC) patients than in healthy subjects. In the present study we examined the relationship between levels of IL-6 and of several acute-phase proteins, including C-reactive protein (CRP), alpha 1-antitrypsin (ATT), alpha 1-acid glycoprotein (AAG), haptoglobin (HPT) and fibrinogen. Eighteen patients were studied and had squamous cell carcinoma of the larynx (n = 9), oral cavity (n = 4), oropharynx (n = 3) and hypopharynx (n = 2). Proteins were measured at three time points before and three time points after surgery. Significant (P < 0.0001) relationships were found between IL-6 and CRP (r = 0.69), and fibrinogen (r = 0.51), whereas no correlation was found with AAT (r = 0.13, P = 0.56), AAG (r = 0.38; P = 0.07) and HPT (r = 0.16; P = 0.46). These data strongly suggest that IL-6 may play a key role in acute-phase protein synthesis in HNC and in regulation of the complex host response to malignancies.

PubMed Disclaimer

References

    1. J Exp Med. 1990 Mar 1;171(3):629-36 - PubMed
    1. Cancer. 1980 Jun 15;45(12):3050-60 - PubMed
    1. J Immunol. 1988 Jan 15;140(2):508-12 - PubMed
    1. Clin Exp Immunol. 1992 Aug;89(2):255-60 - PubMed
    1. Cancer. 1992 Aug 1;70(3):559-68 - PubMed